Guity Farahmand, MD
Nephrology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
- Since medical school
- 17 years
- State University of New York at Buffalo School of Medicine, 2009
Offices
1 location · West Coast Kidney · 56 clinicians in this group
Looking this up.
Hospitals listed: 052610 · 052721 · 052815 · 552600 · 552717 · 557754 · Alameda Hospital · Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Highland Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Farahmand’s office at (510) 451-0996 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A116388 · Current
Licensed to practise in California · since 2011 · expires 2027-04-30 · State University of New York at Buffalo School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Nephrology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alameda HospitalAlameda, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Alameda Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 4 the same, 0 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0 to 2.12) · 119 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.45 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.3 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.7 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 532 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,887 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,916 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.37 (0.77 to 5.96) · 80 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (0.58 to 4.02) · 85 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 1.23) · 1,359 cases | No different | Jul 2022 – Jun 2024 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 98 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.4 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -3.6 · 242 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 244 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 40 cases | None | Jul 2023 – Jun 2025 |
What patients said (319 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$312,641
Medicare paid this office $312,641 for 551 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 40 | $94,486 | $313 |
| Return visit (30+ min) | 197 | $59,630 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 213 | $46,566 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 152 | $22,426 | $69 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 127 | $15,767 | $113 |
See all 18 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 40 | $94,486 | $313 |
| Return visit (30+ min) | 197 | $59,630 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 213 | $46,566 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 152 | $22,426 | $69 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 127 | $15,767 | $113 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 21 | $9,796 | $265 |
| Hemodialysis procedure with physician evaluation | 70 | $7,614 | $62 |
| Transitional care management services for problem of high complexity | 22 | $6,599 | $264 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 197 | $6,285 | $14 |
| Long return visit (40+ min) | 38 | $5,893 | $147 |
| Critical care, first 30-74 minutes | 25 | $4,413 | $177 |
| New patient visit (45+ min) | 31 | $4,355 | $140 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 14 | $3,730 | $59 |
| Telephone medical discussion with physician, 5-10 minutes | 38 | $2,480 | $46 |
| Short return visit (20+ min) | 27 | $2,349 | $78 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 14 | $1,932 | $46 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,052 | $75 |
| Advance care planning, first 30 minutes | 12 | $805 | $67 |
Who their Medicare patients are
551 Original Medicare patients in 2024. Average age 75 · Under 65 14% · 85 and older 19% · Women 49% · Also on Medicaid 65% · Health risk score 4.33. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 65% · Heart failure 57% · Coronary heart disease 46% · Atrial fibrillation 40% · COPD 28% · Depression 26% · Stroke 23% · Dementia 21% · Cancer 17%.
The office billed $836,132, Medicare allowed $408,507 and paid $312,641; for 2,818 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 551 | 2,818 | 75 | 4.33 | $836,132 | $312,641 |
| 2023 | 529 | 2,338 | 75 | 4.25 | $772,336 | $293,516 |
| 2022 | 520 | 2,265 | 75 | 4.01 | $752,642 | $263,241 |
| 2021 | 523 | 2,195 | 73 | 4.16 | $798,758 | $314,701 |
| 2020 | 466 | 2,097 | 72 | 4.38 | $669,056 | $260,312 |
| 2019 | 521 | 1,772 | 72 | 4.39 | $563,188 | $214,324 |
| 2018 | 546 | 2,154 | 73 | 4.57 | $639,785 | $242,854 |
| 2017 | 435 | 2,005 | 71 | 4.99 | $451,048 | $174,472 |
| 2016 | 506 | 3,011 | 72 | 4.84 | $511,914 | $227,726 |
| 2015 | 221 | 763 | 71 | 4.79 | $144,187 | $68,194 |
| 2013 | 48 | 128 | 70 | 2.71 | $38,013 | $10,968 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 32 | $84,606 | $320 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 227 | $56,376 | $107 |
| Return visit (30+ min) | 152 | $30,530 | $96 |
| Long return visit (40+ min) | 121 | $27,364 | $135 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 164 | $20,947 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 126 | $18,878 | $72 |
| Hemodialysis procedure with physician evaluation | 85 | $12,268 | $64 |
| Telephone medical discussion with physician, 21-30 minutes | 36 | $5,394 | $75 |
| New patient visit (60+ min) | 22 | $4,411 | $201 |
| Telephone medical discussion with physician, 5-10 minutes | 41 | $2,929 | $47 |
| Advance care planning, first 30 minutes | 21 | $1,516 | $63 |
| Short return visit (20+ min) | 15 | $1,293 | $68 |
2022: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 29 | $76,114 | $318 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 236 | $51,075 | $91 |
| Long return visit (40+ min) | 114 | $25,565 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 129 | $17,527 | $119 |
| Return visit (30+ min) | 104 | $15,188 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 114 | $14,105 | $64 |
| Telephone medical discussion with physician, 21-30 minutes | 72 | $10,034 | $67 |
| Hemodialysis procedure with physician evaluation | 71 | $8,678 | $65 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 16 | $6,272 | $273 |
| New patient visit (60+ min) | 32 | $5,893 | $184 |
| Telephone medical discussion with physician, 5-10 minutes | 60 | $4,538 | $38 |
| Critical care, first 30-74 minutes | 15 | $2,680 | $179 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $1,728 | $54 |
| Advance care planning, first 30 minutes | 14 | $984 | $66 |
2021: 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 61 | $112,872 | $324 |
| Long return visit (40+ min) | 152 | $52,128 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 230 | $49,539 | $93 |
| Return visit (30+ min) | 108 | $16,866 | $111 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 111 | $14,820 | $122 |
| New patient visit (60+ min) | 48 | $8,851 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 81 | $8,657 | $64 |
| Hemodialysis procedure with physician evaluation | 69 | $8,529 | $65 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 16 | $5,237 | $276 |
| Telephone medical discussion with physician, 21-30 minutes | 33 | $5,094 | $124 |
| Transitional care management services for problem of high complexity | 16 | $4,599 | $271 |
| Telephone medical discussion with physician, 5-10 minutes | 41 | $3,961 | $55 |
| Short return visit (20+ min) | 20 | $1,679 | $73 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $1,671 | $88 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 43 | $1,373 | $22 |
2020: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $92,169 | $263 |
| Long return visit (40+ min) | 148 | $50,041 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 208 | $42,544 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 130 | $18,924 | $125 |
| Hemodialysis procedure with physician evaluation | 69 | $9,623 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $8,884 | $66 |
| Return visit (30+ min) | 68 | $8,248 | $89 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 20 | $6,400 | $213 |
| New patient visit (60+ min) | 38 | $5,807 | $153 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $3,685 | $100 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 41 | $1,915 | $24 |
2019: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 50 | $72,949 | $255 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 225 | $42,952 | $90 |
| Long return visit (40+ min) | 139 | $34,505 | $122 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 136 | $17,331 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $13,884 | $64 |
| New patient visit (60+ min) | 45 | $7,542 | $168 |
| Hemodialysis procedure with physician evaluation | 68 | $6,761 | $64 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $6,070 | $217 |
| Return visit (30+ min) | 45 | $5,231 | $92 |
| Dialysis procedure including 1 evaluation | 11 | $1,397 | $78 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $406 | $21 |
| Injection of drug or substance under skin or into muscle | 11 | $363 | $13 |
2018: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 39 | $71,164 | $255 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 219 | $39,774 | $91 |
| Long return visit (40+ min) | 117 | $32,311 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 210 | $25,549 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 165 | $22,376 | $120 |
| Return visit (30+ min) | 85 | $12,465 | $85 |
| New patient visit (60+ min) | 59 | $11,008 | $187 |
| Hemodialysis procedure with physician evaluation | 79 | $8,230 | $62 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $7,331 | $216 |
| Home dialysis services per month (20 years or older) | 12 | $5,750 | $192 |
| Injection of drug or substance under skin or into muscle | 26 | $1,316 | $19 |
2017: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 31 | $37,146 | $251 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 190 | $29,095 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 155 | $26,544 | $91 |
| Long return visit (40+ min) | 84 | $18,558 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 101 | $13,354 | $119 |
| Return visit (30+ min) | 65 | $10,204 | $90 |
| Hemodialysis procedure with physician evaluation | 80 | $9,943 | $63 |
| New patient visit (60+ min) | 48 | $7,894 | $164 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,486 | $170 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $6,134 | $212 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $2,745 | None |
| Dialysis procedure including 1 evaluation | 11 | $1,748 | $76 |
| Injection of drug or substance under skin or into muscle | 20 | $1,119 | $25 |
2016: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 296 | $68,879 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 204 | $37,989 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 193 | $31,930 | $62 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 19 | $28,694 | $247 |
| Hemodialysis procedure with physician evaluation | 92 | $15,548 | $62 |
| Long return visit (40+ min) | 65 | $13,652 | $122 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $7,220 | None |
| New patient visit (60+ min) | 39 | $6,422 | $165 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 18 | $5,851 | $209 |
| Return visit (30+ min) | 32 | $4,390 | $93 |
| Injection of drug or substance under skin or into muscle | 21 | $1,101 | $24 |
2015: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 154 | $31,943 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 97 | $16,974 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $7,322 | $62 |
| Hemodialysis procedure with physician evaluation | 45 | $4,870 | $59 |
2013: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,635 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,302 | $157 |
| Hospital discharge day management, more than 30 minutes | 24 | $2,165 | $90 |
Medicaid work
$69,240 in 2024
Medicaid paid $69,240 for 1,074 billed services this clinician did in 2024, up to 44 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 221 | $36,165 |
| Return visit (30+ min) | 352 | $14,728 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 283 | $11,649 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 140 | $4,308 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 64 | $1,517 |
| Long return visit (40+ min) | 14 | $872 |
| 2024 | 1,074 | 6 | 44 | $69,240 |
| 2023 | 1,335 | 7 | 37 | $94,159 |
| 2022 | 1,156 | 7 | 31 | $63,859 |
| 2021 | 1,430 | 6 | 50 | $72,407 |
| 2020 | 1,328 | 7 | 41 | $67,257 |
| 2019 | 1,248 | 6 | 38 | $52,577 |
| 2018 | 1,485 | 10 | 34 | $51,898 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 277 | $46,191 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 448 | $20,125 |
| Long return visit (40+ min) | 166 | $10,735 |
| Return visit (30+ min) | 201 | $8,129 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 195 | $6,981 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 35 | $1,233 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 13 | $764 |
2022
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 281 | $36,112 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 453 | $13,629 |
| Long return visit (40+ min) | 217 | $9,787 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 138 | $2,706 |
| Return visit (30+ min) | 32 | $1,210 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 22 | $296 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 13 | $118 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 449 | $44,156 |
| Long return visit (40+ min) | 356 | $14,481 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 511 | $11,739 |
| Return visit (30+ min) | 51 | $1,276 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 49 | $673 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 14 | $82 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 460 | $36,584 |
| Long return visit (40+ min) | 386 | $17,361 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 407 | $11,869 |
| Return visit (30+ min) | 13 | $853 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 32 | $345 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 18 | $151 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 12 | $95 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 323 | $20,377 |
| Long return visit (40+ min) | 299 | $15,332 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 413 | $12,477 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 144 | $3,412 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 43 | $631 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 26 | $347 |
2018
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 329 | $17,222 |
| Long return visit (40+ min) | 274 | $14,031 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 340 | $8,789 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 316 | $6,409 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 105 | $2,874 |
| Return visit (30+ min) | 63 | $1,426 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $678 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 19 | $370 |
| New patient visit (60+ min) | 12 | $52 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 14 | $48 |
Drugs they prescribed that Part D paid
$1,764,276
Pharmacies billed $1,764,276 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,622) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,782 generic and fewer than 11 brand-name prescriptions · $1,764,276 in drug cost · 28 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Krystexxa | 26 | $732,574 | $28,176 |
| Jardiance | 146 | $168,183 | $1,152 |
| Farxiga | 155 | $133,661 | $862 |
| Ozempic | 79 | $121,646 | $1,540 |
| Veltassa | 43 | $64,773 | $1,506 |
See all 56 drugs
| Krystexxa | 26 | $732,574 | $28,176 |
| Jardiance | 146 | $168,183 | $1,152 |
| Farxiga | 155 | $133,661 | $862 |
| Ozempic | 79 | $121,646 | $1,540 |
| Veltassa | 43 | $64,773 | $1,506 |
| Trulicity | 27 | $57,298 | $2,122 |
| Kerendia | 51 | $55,250 | $1,083 |
| Rybelsus | 23 | $54,660 | $2,377 |
| Xphozah | 18 | $51,772 | $2,876 |
| Velphoro | 15 | $50,343 | $3,356 |
| Procrit | 46 | $33,274 | $723 |
| Lokelma | 23 | $29,233 | $1,271 |
| Entresto | 20 | $18,100 | $905 |
| Sevelamer Carbonate | 53 | $15,474 | $292 |
| Wegovy | 12 | $15,260 | $1,272 |
| Rayaldee | 11 | $14,593 | $1,327 |
| Dapagliflozin | 17 | $13,396 | $788 |
| Carvedilol Er | 16 | $8,272 | $517 |
| Invokana | 12 | $6,909 | $576 |
| Retacrit | 16 | $6,589 | $412 |
| Febuxostat | 11 | $3,244 | $295 |
| Cinacalcet | 23 | $2,287 | $99 |
| Bumetanide | 39 | $2,187 | $56 |
| Calcium Acetate | 13 | $1,591 | $122 |
| Amlodipine Besylate | 190 | $1,181 | $6 |
| Losartan | 113 | $1,079 | $10 |
| Furosemide | 210 | $1,061 | $5 |
| Calcitriol | 44 | $907 | $21 |
| Potassium Chloride | 42 | $903 | $21 |
| Carvedilol | 110 | $873 | $8 |
| Magnesium Sulfate | 15 | $831 | $55 |
| Allopurinol | 82 | $771 | $9 |
| Doxazosin Mesylate | 31 | $760 | $25 |
| Nifedipine Er | 16 | $749 | $47 |
| Olmesartan Medoxomil | 29 | $730 | $25 |
| Tamsulosin | 42 | $644 | $15 |
| Lisinopril | 88 | $564 | $6 |
| Atorvastatin | 48 | $550 | $11 |
| Dextrose in Water | 11 | $492 | $45 |
| Hydralazine | 52 | $488 | $9 |
| Clonidine | 11 | $392 | $36 |
| Metoprolol | 39 | $324 | $8 |
| Hydrochlorothiazide | 69 | $318 | $5 |
| Omeprazole | 12 | $280 | $23 |
| Metolazone | 17 | $208 | $12 |
| Gabapentin | 30 | $193 | $6 |
| Spironolactone | 24 | $176 | $7 |
| Pantoprazole | 14 | $140 | $10 |
| Famotidine | 20 | $129 | $6 |
| Enalapril Maleate | 15 | $103 | $7 |
| Lactulose | 11 | $99 | $9 |
| Prednisone | 18 | $63 | $4 |
| Metformin Hcl Er | 12 | $58 | $5 |
| Cephalexin | 14 | $44 | $3 |
| Sodium Chloride | 26 | $43 | $2 |
| Diphenhydramine | 23 | $40 | $2 |
Year by year
| 2024 | 2,622 | 308 | 0% (0) | None | $1,764,276 |
| 2023 | 2,430 | 273 | 0% (0) | 28% | $1,243,437 |
| 2022 | 1,966 | 238 | None | None | $630,510 |
| 2021 | 1,574 | 205 | None | None | $360,265 |
| 2020 | 1,158 | 179 | None | None | $244,645 |
| 2019 | 1,027 | 173 | 2% (20) | 21% | $158,604 |
| 2018 | 1,036 | 151 | 1% (15) | 19% | $148,478 |
| 2017 | 607 | 106 | None | 23% | $153,288 |
| 2016 | 303 | 67 | None | 18% | $36,855 |
| 2015 | 81 | 17 | None | None | $1,947 |
| 2013 | 19 | None | None | None | $464 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 46 drugs
| Farxiga | 170 | $237,643 | $1,398 |
| Jardiance | 116 | $160,996 | $1,388 |
| Trulicity | 45 | $104,286 | $2,317 |
| Ozempic | 69 | $91,043 | $1,319 |
| Renvela | 24 | $65,930 | $2,747 |
| Veltassa | 35 | $60,007 | $1,714 |
| Procrit | 69 | $50,466 | $731 |
| Velphoro | 14 | $37,375 | $2,670 |
| Lokelma | 13 | $29,861 | $2,297 |
| Sevelamer Carbonate | 36 | $25,945 | $721 |
| Kerendia | 19 | $24,035 | $1,265 |
| Retacrit | 26 | $17,069 | $657 |
| Carvedilol Er | 15 | $8,756 | $584 |
| Cinacalcet | 15 | $7,581 | $505 |
| Febuxostat | 12 | $3,475 | $290 |
| Tamsulosin | 55 | $3,227 | $59 |
| Bumetanide | 25 | $2,982 | $119 |
| Carvedilol | 148 | $2,971 | $20 |
| Amlodipine Besylate | 177 | $2,888 | $16 |
| Losartan | 94 | $2,756 | $29 |
| Furosemide | 170 | $2,342 | $14 |
| Calcitriol | 69 | $2,319 | $34 |
| Nifedipine Er | 44 | $2,298 | $52 |
| Olmesartan Medoxomil | 31 | $2,170 | $70 |
| Potassium Chloride | 37 | $2,039 | $55 |
| Clonidine | 11 | $1,782 | $162 |
| Hydralazine | 84 | $1,680 | $20 |
| Lisinopril | 76 | $1,367 | $18 |
| Atorvastatin | 42 | $1,332 | $32 |
| Calcium Acetate | 16 | $1,218 | $76 |
| Allopurinol | 49 | $741 | $15 |
| Doxazosin Mesylate | 20 | $709 | $35 |
| Hydrochlorothiazide | 54 | $610 | $11 |
| Lactulose | 22 | $548 | $25 |
| Enalapril Maleate | 29 | $517 | $18 |
| Isosorbide Mononitrate Er | 19 | $491 | $26 |
| Albuterol Sulfate Hfa | 13 | $364 | $28 |
| Metoprolol | 14 | $330 | $24 |
| Hydroxyzine | 19 | $313 | $16 |
| Atenolol | 11 | $304 | $28 |
| Gabapentin | 17 | $291 | $17 |
| Metoprolol | 13 | $219 | $17 |
| Clonidine | 13 | $211 | $16 |
| Glipizide Er | 12 | $156 | $13 |
| Cephalexin | 11 | $82 | $7 |
| Sure Comfort | 13 | $59 | $5 |
2022: 37 drugs
| Farxiga | 126 | $145,804 | $1,157 |
| Jardiance | 76 | $91,642 | $1,206 |
| Velphoro | 22 | $86,547 | $3,934 |
| Renvela | 15 | $54,363 | $3,624 |
| Sevelamer Carbonate | 59 | $42,803 | $725 |
| Veltassa | 28 | $30,618 | $1,094 |
| Retacrit | 52 | $29,313 | $564 |
| Procrit | 13 | $16,167 | $1,244 |
| Potassium Chloride | 34 | $4,205 | $124 |
| Calcium Acetate | 23 | $3,335 | $145 |
| Calcitriol | 97 | $2,836 | $29 |
| Carvedilol | 148 | $2,045 | $14 |
| Tamsulosin | 76 | $2,001 | $26 |
| Hydralazine | 61 | $1,801 | $30 |
| Nifedipine Er | 36 | $1,782 | $49 |
| Amlodipine Besylate | 151 | $1,640 | $11 |
| Clonidine | 13 | $1,443 | $111 |
| Furosemide | 153 | $1,309 | $9 |
| Doxazosin Mesylate | 34 | $1,154 | $34 |
| Losartan | 81 | $986 | $12 |
| Bumetanide | 14 | $966 | $69 |
| Allopurinol | 47 | $778 | $17 |
| Albuterol Sulfate Hfa | 17 | $615 | $36 |
| Isosorbide Mononitrate Er | 16 | $569 | $36 |
| Omeprazole | 22 | $474 | $22 |
| Lactulose | 12 | $453 | $38 |
| Glipizide Er | 25 | $424 | $17 |
| Enalapril Maleate | 40 | $402 | $10 |
| Lisinopril | 45 | $369 | $8 |
| Metoprolol | 13 | $364 | $28 |
| Atorvastatin | 31 | $316 | $10 |
| Valsartan-Hydrochlorothiazide | 12 | $299 | $25 |
| Hydrochlorothiazide | 34 | $273 | $8 |
| Constulose | 11 | $256 | $23 |
| Metformin | 17 | $231 | $14 |
| Propranolol | 11 | $122 | $11 |
| Cephalexin | 14 | $82 | $6 |
2021: 34 drugs
| Renvela | 24 | $68,615 | $2,859 |
| Velphoro | 12 | $60,595 | $5,050 |
| Veltassa | 32 | $40,086 | $1,253 |
| Jardiance | 45 | $35,988 | $800 |
| Sevelamer Carbonate | 40 | $31,738 | $793 |
| Farxiga | 34 | $30,366 | $893 |
| Procrit | 16 | $17,194 | $1,075 |
| Cinacalcet | 14 | $6,801 | $486 |
| Retacrit | 20 | $4,722 | $236 |
| Potassium Chloride | 32 | $4,330 | $135 |
| Calcium Acetate | 27 | $3,655 | $135 |
| Febuxostat | 16 | $3,558 | $222 |
| Clonidine | 13 | $2,593 | $199 |
| Calcitriol | 90 | $2,395 | $27 |
| Carvedilol | 162 | $1,999 | $12 |
| Bumetanide | 21 | $1,697 | $81 |
| Furosemide | 153 | $1,676 | $11 |
| Tamsulosin | 68 | $1,350 | $20 |
| Amlodipine Besylate | 102 | $1,235 | $12 |
| Allopurinol | 56 | $1,063 | $19 |
| Hydralazine | 54 | $982 | $18 |
| Doxazosin Mesylate | 20 | $700 | $35 |
| Nifedipine Er | 23 | $699 | $30 |
| Midodrine | 12 | $601 | $50 |
| Losartan | 47 | $501 | $11 |
| Colchicine | 17 | $462 | $27 |
| Labetalol | 13 | $443 | $34 |
| Propranolol | 20 | $338 | $17 |
| Atorvastatin | 20 | $274 | $14 |
| Lisinopril | 37 | $264 | $7 |
| Enalapril Maleate | 21 | $162 | $8 |
| Gabapentin | 16 | $142 | $9 |
| Hydrochlorothiazide | 26 | $105 | $4 |
| Metformin | 13 | $38 | $3 |
2020: 28 drugs
| Renvela | 21 | $40,806 | $1,943 |
| Veltassa | 29 | $35,929 | $1,239 |
| Procrit | 19 | $27,472 | $1,446 |
| Sevelamer Carbonate | 26 | $16,329 | $628 |
| Lokelma | 12 | $8,510 | $709 |
| Calcium Acetate | 25 | $3,331 | $133 |
| Febuxostat | 18 | $3,264 | $181 |
| Calcitriol | 64 | $1,929 | $30 |
| Metolazone | 17 | $1,572 | $92 |
| Furosemide | 89 | $1,251 | $14 |
| Potassium Chloride | 33 | $1,212 | $37 |
| Bumetanide | 23 | $1,076 | $47 |
| Carvedilol | 100 | $1,028 | $10 |
| Amlodipine Besylate | 109 | $855 | $8 |
| Tamsulosin | 61 | $819 | $13 |
| Allopurinol | 64 | $737 | $12 |
| Hydrocortisone | 17 | $337 | $20 |
| Lisinopril | 23 | $319 | $14 |
| Hydralazine | 20 | $264 | $13 |
| Metoprolol | 18 | $197 | $11 |
| Losartan | 25 | $176 | $7 |
| Gabapentin | 23 | $136 | $6 |
| Atorvastatin | 11 | $127 | $12 |
| Hydrochlorothiazide | 21 | $114 | $5 |
| Clonidine | 11 | $96 | $9 |
| Benazepril | 12 | $95 | $8 |
| Cephalexin | 15 | $93 | $6 |
| Glipizide | 13 | $84 | $6 |
2019: 22 drugs
| Procrit | 39 | $30,952 | $794 |
| Sevelamer Carbonate | 33 | $27,572 | $836 |
| Renvela | 14 | $25,158 | $1,797 |
| Veltassa | 16 | $12,855 | $803 |
| Lokelma | 11 | $7,285 | $662 |
| Calcium Acetate | 35 | $4,033 | $115 |
| Allopurinol | 74 | $1,217 | $16 |
| Metolazone | 15 | $1,107 | $74 |
| Furosemide | 84 | $1,063 | $13 |
| Amlodipine Besylate | 131 | $874 | $7 |
| Carvedilol | 86 | $856 | $10 |
| Tamsulosin | 51 | $787 | $15 |
| Potassium Chloride | 16 | $458 | $29 |
| Lisinopril | 39 | $305 | $8 |
| Calcitriol | 11 | $259 | $24 |
| Cephalexin | 18 | $165 | $9 |
| Losartan | 25 | $164 | $7 |
| Omeprazole | 13 | $130 | $10 |
| Hydrochlorothiazide | 22 | $111 | $5 |
| Famotidine | 15 | $107 | $7 |
| Tramadol | 19 | $102 | $5 |
| Prednisone | 20 | $85 | $4 |
2018: 26 drugs
| Renvela | 30 | $50,654 | $1,688 |
| Procrit | 43 | $20,050 | $466 |
| Sevelamer Carbonate | 28 | $16,851 | $602 |
| Veltassa | 16 | $11,931 | $746 |
| Calcium Acetate | 24 | $2,436 | $102 |
| Allopurinol | 74 | $983 | $13 |
| Potassium Chloride | 30 | $901 | $30 |
| Metolazone | 23 | $810 | $35 |
| Furosemide | 107 | $776 | $7 |
| Tamsulosin | 38 | $728 | $19 |
| Carvedilol | 93 | $670 | $7 |
| Midodrine | 13 | $572 | $44 |
| Enalapril Maleate | 14 | $553 | $40 |
| Amlodipine Besylate | 88 | $511 | $6 |
| Hydralazine | 12 | $394 | $33 |
| Lisinopril | 48 | $216 | $5 |
| Cephalexin | 17 | $202 | $12 |
| Warfarin | 24 | $189 | $8 |
| Losartan | 23 | $175 | $8 |
| Prednisone | 12 | $125 | $10 |
| Pantoprazole | 12 | $96 | $8 |
| Omeprazole | 17 | $94 | $6 |
| Hydrochlorothiazide | 23 | $93 | $4 |
| Gabapentin | 15 | $88 | $6 |
| Montelukast | 11 | $83 | $8 |
| Tramadol | 15 | $66 | $4 |
2017: 13 drugs
| Renvela | 33 | $63,480 | $1,924 |
| Allopurinol | 58 | $676 | $12 |
| Calcium Acetate | 12 | $594 | $50 |
| Metolazone | 12 | $535 | $45 |
| Potassium Chloride | 16 | $487 | $30 |
| Tamsulosin | 22 | $443 | $20 |
| Furosemide | 81 | $284 | $4 |
| Carvedilol | 42 | $250 | $6 |
| Lisinopril | 37 | $146 | $4 |
| Amlodipine Besylate | 32 | $140 | $4 |
| Losartan | 20 | $124 | $6 |
| Hydrochlorothiazide | 23 | $116 | $5 |
| Ciprofloxacin | 12 | $81 | $7 |
2016: 10 drugs
| Calcium Acetate | 12 | $742 | $62 |
| Metolazone | 15 | $418 | $28 |
| Allopurinol | 17 | $204 | $12 |
| Furosemide | 31 | $152 | $5 |
| Carvedilol | 14 | $138 | $10 |
| Amlodipine Besylate-Benazepril | 11 | $137 | $12 |
| Amlodipine Besylate | 19 | $100 | $5 |
| Hydrochlorothiazide | 17 | $84 | $5 |
| Lisinopril | 11 | $83 | $8 |
| Atorvastatin | 12 | $61 | $5 |
2015: 1 drug
| Labetalol | 12 | $360 | $30 |
Money from drug and device companies
$2,186 in 2025
| 2025 | 17 | 96 | None | $2,186 |
| 2024 | 16 | 69 | None | $1,505 |
| 2023 | 15 | 72 | None | $1,350 |
| 2022 | 8 | 16 | None | $347 |
| 2021 | 3 | 15 | None | $300 |
| 2020 | 4 | 8 | None | $161 |
| 2019 | 4 | 5 | None | $94 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Fresenius USA Marketing | Velphoro | $436 | 22 payments
|
| Travere Therapeutics | None | $308 | 11 payments
|
| Novo Nordisk | Wegovy | $202 | 13 payments
|
| Amgen | Krystexxa | $200 | 7 payments
|
| Calliditas Therapeutics US | Tarpeyo | $185 | 10 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $176 | 6 payments
|
See all 96 published payments
| Travere Therapeutics | Meals · 2025-12-12 | None | $18 |
| Scpharmaceuticals | Meals · 2025-12-11 | Furoscix | $25 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-09 | Kerendia | $24 |
| Calliditas Therapeutics US | Meals · 2025-12-09 | Tarpeyo | $18 |
| ANI Pharmaceuticals | Meals · 2025-12-08 | Purified Cortrophin Gel | $33 |
| Otsuka America Pharmaceutical | Meals · 2025-12-05 | Voyxact | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Farxiga | $19 |
| Amgen | Meals · 2025-12-01 | Krystexxa | $23 |
| Fresenius USA Marketing | Meals · 2025-11-24 | Velphoro | $15 |
| Mallinckrodt Hospital Products | Meals · 2025-11-22 | Acthar | $30 |
| ANI Pharmaceuticals | Meals · 2025-11-18 | Purified Cortrophin Gel | $35 |
| Otsuka America Pharmaceutical | Meals · 2025-11-06 | Jynarque | $29 |
| Mallinckrodt Hospital Products | Meals · 2025-11-04 | Acthar | $32 |
| Fresenius USA Marketing | Meals · 2025-11-04 | Velphoro | $23 |
| Apellis Pharmaceuticals | Meals · 2025-10-25 | Empaveli | $27 |
| Amgen | Meals · 2025-10-23 | Tavneos | $30 |
| Travere Therapeutics | Meals · 2025-10-17 | None | $38 |
| ANI Pharmaceuticals | Meals · 2025-10-16 | Purified Cortrophin Gel | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-13 | Farxiga | $26 |
| Fresenius USA Marketing | Meals · 2025-10-10 | Velphoro | $7 |
| Fresenius USA Marketing | Meals · 2025-10-10 | Velphoro | $17 |
| Novo Nordisk | Meals · 2025-10-09 | Wegovy | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-10-07 | Jynarque | $26 |
| Travere Therapeutics | Meals · 2025-10-07 | None | $16 |
| Fresenius USA Marketing | Meals · 2025-09-26 | Velphoro | $3 |
| Fresenius USA Marketing | Meals · 2025-09-26 | Velphoro | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-19 | Jardiance | $25 |
| Amgen | Meals · 2025-09-19 | Krystexxa | $28 |
| Travere Therapeutics | Meals · 2025-09-19 | None | $30 |
| Novo Nordisk | Meals · 2025-09-18 | Wegovy | $25 |
| Novo Nordisk | Meals · 2025-09-18 | Wegovy | $3 |
| Novo Nordisk | Meals · 2025-09-16 | Wegovy | $16 |
| Mallinckrodt Hospital Products | Meals · 2025-09-13 | Acthar | $37 |
| Fresenius USA Marketing | Meals · 2025-09-11 | Velphoro | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-09 | Farxiga | $18 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-09 | Kerendia | $23 |
| Fresenius USA Marketing | Meals · 2025-09-08 | Velphoro | $23 |
| ANI Pharmaceuticals | Meals · 2025-09-08 | Purified Cortrophin Gel | $18 |
| Travere Therapeutics | Meals · 2025-09-05 | None | $30 |
| Travere Therapeutics | Meals · 2025-08-29 | None | $26 |
| Calliditas Therapeutics US | Meals · 2025-08-28 | Tarpeyo | $2 |
| Calliditas Therapeutics US | Meals · 2025-08-28 | Tarpeyo | $4 |
| Calliditas Therapeutics US | Meals · 2025-08-28 | Tarpeyo | $5 |
| Calliditas Therapeutics US | Meals · 2025-08-28 | Tarpeyo | $35 |
| Calliditas Therapeutics US | Meals · 2025-08-21 | Tarpeyo | $31 |
| Lilly USA | Meals · 2025-08-20 | Jardiance | $31 |
| Fresenius USA Marketing | Meals · 2025-08-15 | Velphoro | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-14 | Jardiance | $27 |
| Travere Therapeutics | Meals · 2025-08-13 | None | $27 |
| ANI Pharmaceuticals | Meals · 2025-08-12 | Purified Cortrophin Gel | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-08-11 | Jynarque | $32 |
| Travere Therapeutics | Meals · 2025-08-08 | None | $34 |
| Amgen | Meals · 2025-07-25 | Krystexxa | $31 |
| Fresenius USA Marketing | Meals · 2025-07-25 | Velphoro | $24 |
| Novo Nordisk | Meals · 2025-07-24 | Wegovy | $26 |
| Fresenius USA Marketing | Meals · 2025-07-01 | Velphoro | $4 |
| Fresenius USA Marketing | Meals · 2025-07-01 | Velphoro | $20 |
| Calliditas Therapeutics US | Meals · 2025-06-13 | Tarpeyo | $28 |
| Fresenius USA Marketing | Meals · 2025-06-09 | Velphoro | $23 |
| ANI Pharmaceuticals | Meals · 2025-06-09 | Purified Cortrophin Gel | $34 |
| Lilly USA | Meals · 2025-06-06 | Jardiance | $25 |
| Fresenius USA Marketing | Meals · 2025-06-05 | Velphoro | $24 |
| Vifor Pharma | Meals · 2025-06-03 | Veltassa | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-30 | Farxiga | $24 |
| Fresenius USA Marketing | Meals · 2025-05-19 | Velphoro | $25 |
| Novo Nordisk | Meals · 2025-05-07 | Wegovy | $10 |
| Calliditas Therapeutics US | Meals · 2025-05-05 | Tarpeyo | $27 |
| Travere Therapeutics | Meals · 2025-05-02 | None | $39 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-01 | Kerendia | $22 |
| Fresenius USA Marketing | Meals · 2025-04-30 | Velphoro | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-28 | Jardiance | $28 |
| Calliditas Therapeutics US | Meals · 2025-04-25 | Tarpeyo | $7 |
| Novo Nordisk | Meals · 2025-04-24 | Wegovy | $8 |
| Amgen | Meals · 2025-04-22 | Krystexxa | $28 |
| Fresenius USA Marketing | Meals · 2025-04-18 | Velphoro | $23 |
| Fresenius USA Marketing | Meals · 2025-04-11 | Velphoro | $23 |
| Novo Nordisk | Meals · 2025-04-04 | Ozempic | $24 |
| Novo Nordisk | Meals · 2025-04-03 | Wegovy | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-02 | Farxiga | $30 |
| Calliditas Therapeutics US | Meals · 2025-03-31 | Tarpeyo | $28 |
| Mallinckrodt Hospital Products | Meals · 2025-03-29 | Acthar | $20 |
| Fresenius USA Marketing | Meals · 2025-03-24 | Velphoro | $24 |
| Travere Therapeutics | Meals · 2025-03-21 | None | $23 |
| Novo Nordisk | Meals · 2025-03-19 | Ozempic | $23 |
| OPKO Pharmaceuticals | Education · 2025-03-17 | Rayaldee | $17 |
| Fresenius USA Marketing | Meals · 2025-03-14 | Velphoro | $24 |
| Novo Nordisk | Meals · 2025-03-12 | Ozempic | $13 |
| Novartis Pharmaceuticals | Meals · 2025-03-04 | Fabhalta | $16 |
| Fresenius USA Marketing | Meals · 2025-02-26 | Velphoro | $22 |
| Novo Nordisk | Meals · 2025-02-19 | Ozempic | $3 |
| Novo Nordisk | Meals · 2025-02-11 | Ozempic | $14 |
| Amgen | Meals · 2025-02-04 | Krystexxa | $25 |
| Travere Therapeutics | Meals · 2025-02-03 | None | $28 |
| Amgen | Meals · 2025-01-13 | Tavneos | $34 |
| OPKO Pharmaceuticals | Education · 2025-01-09 | Rayaldee | $21 |
| Fresenius USA Marketing | Meals · 2025-01-08 | Velphoro | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,505
| Novo Nordisk | Ozempic | $203 | 13 payments
|
| Amgen | Krystexxa | $187 | 8 payments
|
| Travere Therapeutics | None | $174 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $150 | 8 payments
|
| Lilly USA | Jardiance | $128 | 4 payments
|
| Fresenius USA Marketing | Velphoro | $115 | 5 payments
|
| Calliditas Therapeutics US | Tarpeyo | $88 | 4 payments
|
| Vifor Pharma | Veltassa | $87 | 3 payments
|
| Ardelyx | Ibsrela | $72 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $67 | 3 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $57 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $55 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $46 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $31 | 1 payment
|
| GlaxoSmithKline | Jesduvroq | $29 | 1 payment
|
| Veloxis Pharmaceuticals | Envarsus | $16 | 1 payment
|
2023: $1,350
| AstraZeneca Pharmaceuticals LP | Farxiga | $361 | 16 payments
|
| Horizon Therapeutics plc | Krystexxa | $213 | 11 payments
|
| Fresenius USA Marketing | Velphoro | $204 | 12 payments
|
| Travere Therapeutics | None | $162 | 10 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $100 | 4 payments
|
| Novo Nordisk | Ozempic | $69 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $46 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $29 | 1 payment
|
| Novartis Pharmaceuticals | None | $29 | 1 payment
|
| Vifor Pharma | Veltassa | $28 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $25 | 1 payment
|
| Ardelyx | Ibsrela | $25 | 1 payment
|
| GlaxoSmithKline | Benlysta | $24 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $18 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $15 | 1 payment
|
2022: $347
| Otsuka America Pharmaceutical | Jynarque | $170 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | None | $40 | 2 payments
|
| Amgen | Tavneos | $29 | 1 payment
|
| Vifor Pharma | Veltassa | $25 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $24 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $22 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $21 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $15 | 1 payment
|
2021: $300
| Otsuka America Pharmaceutical | Jynarque | $222 | 11 payments
|
| Daiichi Sankyo | Injectafer | $63 | 3 payments
|
| Vifor Pharma | Veltassa | $14 | 1 payment
|
2020: $161
| Daiichi Sankyo | Injectafer | $46 | 2 payments
|
| Relypsa | Veltassa | $43 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $38 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $35 | 2 payments
|
2019: $94
| AstraZeneca Pharmaceuticals LP | Lokelma | $36 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $22 | 1 payment
|
| Relypsa | Veltassa | $20 | 1 payment
|
| Daiichi Sankyo | Injectafer | $16 | 1 payment
|
Professional record
- NPI
- 1700017175
- Licence
- CA A116388California A116388: Current · expires 2027-04-30
- Trained
- State University of New York at Buffalo School of Medicine, 2009 · 17 years ago
- Group
- West Coast Kidney
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- 3300 Webster St, Suite 804, Oakland, CA, 94609
- NPI first listed
- 2009-08-04
- NPI last updated
- 2016-12-19
This is when the NPI record was last certified, not a medical board exam.